GATWICK, United Kingdom - Tuesday, March 19th 2013 [ME NewsWire]

(BUSINESS WIRE)-- Systagenix and Team Sky have announced an extension of their sponsorship agreement which will run until the end of 2013. Systagenix will continue to supply Team Sky – the world’s number 1 professional cycling team – with its advanced wound care products and clinical support through 2013.

Simon Jackson, Vice President – Europe at Systagenix said "We are delighted to be extending our partnership with Team Sky. Everyone here at Systagenix is extremely proud to be associated with Team Sky and the amazing success the team has had. We work closely with the team’s doctors and medical staff who have found our ADAPTIC TOUCH®, INADINE® and TIELLE® dressings in particular a real help for riders who have crashed to ensure they heal as fast as possible and with minimal pain.”

Team Sky Doctor, Alan Farrell said "Systagenix have proved time and time again that they are the experts when ... Read more »

INGELHEIM, Germany - Tuesday, March 19th 2013 [ME NewsWire]

(BUSINESS WIRE)-- For Non-U.S. and Non-U.K. Media

Boehringer Ingelheim and Eli Lilly and Company announced today the initiation of a Phase IIIb trial to evaluate the glycaemic efficacy and safety of linagliptin in type 2 diabetes patients with prevalent albuminuria, and urinary albumin-to-creatinine (UACR) ratio 30-3000 mg/g creatinine, in addition to current standard therapy for diabetic nephropathy. The name of the clinical trial is MARLINA™*.

"With linagliptin, no dose adjustment is required even for patients with declining renal function”, said Professor Per-Henrik Groop, Professor of Nephrology, and Chief Physician at the Division of Nephrology, Helsinki University Central Hospital, Helsinki, Finland and Principal Investigator of the MARLINA™ trial. "What is of particular interest is that this study will evaluate the glycaemic efficacy and safety of linagliptin therapy in patients with type 2 diabetes ... Read more »

HIGH POINT, N.C. - Tuesday, March 19th 2013 [BUSINESS WIRE/ ME NewsWire]

TransTech Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for TTP488, a new small-molecule chemical compound being developed for the treatment of Alzheimer’s disease. TTP488 prevents the interaction of amyloid beta (Aβ), a material found in the cells of Alzheimer’s patients, and a member of the immunoglobulin supergene family of molecules known as the Receptor for Advanced Glycation Endproducts (RAGE). TTP488 is the first drug related to RAGE, a relatively new biological target in Alzheimer’s disease research, with demonstrated success in multiple clinical trials. TransTech Pharma discovered, developed and owns the rights to this drug candidate.

The FDA’s Fast Track designation is granted to development products intended for the treatment of a serious or life-threatening condition that demonstrate the potential to address unmet medical n ... Read more »

HONG KONG - Tuesday, March 19th 2013 [ME NewsWire]

(BUSINESS WIRE)-- The latest issue of Compliance Insider®, a publication for Chief Compliance Officers published by The Red Flag Group, looks at solutions to common challenges faced by global companies in the development of a compliance framework.

As legal and regulatory requirements increase, so does the importance of a robust, sustainable compliance framework. Senior compliance executives understand the need to align their efforts with a company’s strategic vision and goals to effectively support business growth, but this is often easier said than done.

Effective compliance frameworks that provide comprehensive protection from risk and stand up to regulatory scrutiny have common attributes including:

    A clear focus on a company’s real risk, achieved by conducting a thorough risk assessment
    Mechanisms for the efficient remediation of potential issues as soon as th ... Read more »